Mesa Hip Ledger helps you prepare for a hip visit

Your notes can make the next hip visit clearer

Start with the exact place that hurts. An ache near the groin may start in the joint, while outer-hip or back soreness can feel different.

Notice what brings on the ache and what settles it. Write down how long soreness lasts after sitting or walking.

Shorter walks, a firm chair, and brief rests may help at home. Physical therapy can guide gentle strength work when you aren't sure how to begin.

Ask your doctor which medicine is safe with your other pills. Don't borrow someone else's medicine or guess about a dose.

A hip visit usually includes questions and a movement exam. An X-ray may be useful when the doctor is concerned about joint wear.

The office spins your blood to prepare platelet-rich plasma, or PRP. Ask what the hip studies found and when a change might appear.

Before paying, get the procedure name and full charge in writing, including every planned visit, each follow-up appointment, and any office fee that could be added later to your bill. If the office won't write it down, don't leave a deposit.

Choose one daily task as your main goal. It can be walking, dressing, climbing stairs, or sleeping more comfortably.

Sudden hip heat and swelling during a fever needs prompt medical help. So does a fall that leaves you unable to stand on the leg.

I'd keep your medicine list, soreness notes, and written questions together. Bring them to the appointment so nothing important gets missed.

Sources

1. Roughly 14 million people in the United States have symptomatic knee osteoarthritis, and more than half of them are under 65 - with nearly 2 million under 45. The market for a cash-pay procedure sold as an alternative to joint replacement is largely working-age people who are being told they are too young for surgery.

   Deshpande BR, et al. — Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity.. Arthritis care & research, 2016. DOI: 10.1002/acr.22897.

2. The study that first mapped the scale of the US direct-to-consumer stem cell industry, finding widespread internet marketing of unapproved stem cell interventions by businesses based in the UNITED STATES - previously assumed to be a phenomenon of countries with lax medical regulation - and concluding that regulators must better oversee this marketplace.

   Turner L, et al. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell stem cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

3. In January 2025 the Federal Trade Commission banned the co-founders of a stem cell institute and their companies from marketing stem cell treatments and ordered them to pay more than $5.1 million in refunds and civil penalties. Deceptive EFFICACY ADVERTISING, not merely unapproved manufacturing, is independently actionable - the FTC polices what a clinic promises as well as what it injects.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.